
Current guidelines from the Joint National Committee on Prevention, zzso zzso and Treatment of High Blood zzso recommend zzso treatment with a zzso zzso but do not provide specific guidance for obese zzso The zzso system is activated in zzso zzso zzso zzso we tested the hypothesis that the oral direct zzso inhibitor zzso could provide additive blood pressure lowering in obese patients with hypertension zzso mass zzso zzso mean sitting zzso blood zzso 95 to 109 zzso zzso who had not responded to 4 weeks of treatment with zzso zzso 25 zzso After a zzso to zzso zzso zzso patients received zzso zzso zzso zzso for 4 zzso 489 zzso were randomly assigned to zzso zzso zzso zzso zzso zzso zzso zzso (5 zzso or zzso for 4 weeks added to zzso zzso zzso followed by 8 weeks on double the initial doses of zzso zzso or zzso After 8 weeks of zzso treatment (4 weeks on the higher zzso zzso lowered blood pressure by zzso zzso zzso significantly more zzso than zzso zzso zzso zzso zzso provided blood pressure reductions similar to those with zzso and zzso zzso and zzso zzso zzso respectively), with similar zzso to zzso zzso event rates were highest with zzso because of a higher zzso of peripheral zzso zzso versus zzso to zzso in other zzso In conclusion, combination treatment with zzso is a highly effective and zzso therapeutic option for obese patients with hypertension who fail to achieve blood pressure control with zzso zzso zzso zzso 

